Stoneridge (SRI) Misses Q2 EPS by 14c, Updates FY Guidance

Stoneridge (NYSE: SRI) reported Q2 EPS of ($0.14), $0.14 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $191.3 million versus the consensus estimate of $185.91 million.

GUIDANCE:

Stoneridge sees FY2021 EPS of $0.20-$0.30, versus the consensus of $0.45. Stoneridge sees FY2021 revenue of $770-790 million, versus the consensus of $772 million.

For earnings history and earnings-related data on Stoneridge (SRI) click here.

You May Also Be Interested In

• Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
• Profound Medical names Richard Fabian as president
• Protagonist Therapeutics (PTGX) PT Raised to $170 at H.C. Wainwright